Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Cullinan Therapeutics heads into its November 6 earnings event with a stark gap between a stubbornly bearish lending market and a Street that has spent the past several weeks nudging targets higher.
The positioning picture tells a story of persistent, if easing, short pressure. Short interest runs at 16.2% of the free float, roughly 9.6 million shares, down from a month-ago peak near 10.5 million but essentially flat on the week. Crucially, the borrow market does not feel stressed: cost to borrow has eased 14% over the past week to just 0.45%, and availability is ample at 526%, meaning there are more than five shares available to borrow for every one already lent out. That is well above the 52-week tightest reading of 354%. Shorts are present in size, but they face no squeeze mechanics. The ORTEX short score of 67.8 reflects the elevated positioning, while the factor rank for short score sits at just the 14th percentile, confirming that bears here are more convicted than in most of the universe. Options lean defensive too: the put/call ratio is 1.25, near its 52-week high of 1.29 and modestly above its 20-day average of 1.17, though the z-score of 0.49 suggests the skew is notable rather than extreme.
The Street is pulling firmly in the other direction. Every recent analyst action has been a reiteration or raise, with no downgrades in the visible record. HC Wainwright lifted its target from $30 to $35 on September 25 and stood by it again this week. BTIG held at $40, having raised from $39 on September 14. Wedbush went to $42 in August from $39. The consensus mean target of $33.45 implies roughly 114% upside to the current price of $15.63, a gap wide enough to reflect genuine uncertainty about probability-weighting rather than simple optimism. The bull case centres on the REZILIENT3 Phase 3 data for zipalertinib, a 65% objective response rate against 8.5-month chemotherapy progression-free survival, a potential FDA filing by year-end 2026, and a February 27, 2027 PDUFA date, all underpinned by up to $130 million in milestone payments from Taiho. The bear case is equally clear: the DCF requires a 95% launch probability for zipalertinib just to get to fair value, assigns only 20% to CLN-978, and flags dilution risk as the share count is modelled rising toward 64.5 million by end-2026. The 12-month forward EPS growth factor ranks at the 88th percentile, reflecting how much the model depends on a single regulatory outcome rather than near-term earnings power.
The ownership register carries some intriguing recent flows. T. Rowe Price added 1.8 million shares to reach 5.9% of the float as of September 30, and State Street added 1.1 million in the same period. BlackRock added 783,000 shares. Those are meaningful additions from large passive and active managers in the most recent quarter. Alongside that, MPM BioImpact holds 15.1% and specialist healthcare manager BVF Partners holds 8.9%, giving the register a concentrated, conviction-driven flavour. On the insider side, all recent trades from Chief Scientific Officer Jennifer Michaelson carry the 10b5-1 disclosure, pre-arranged plan sales exercising options at $4.30 and selling into the open market, standard compensation mechanics that carry limited signal about management's near-term view of the stock.
Retail attention is worth flagging as a separate data point. The ORTEX alt data layer records a Wikipedia-views z-score of 2.5 as of September 22, meaning attention is running well above the stock's own 90-day baseline. That is a measure of interest, not of direction, but it tracks with the fact that CGEM is up more than 100% year-to-date even after a 29% pullback over the past month. The recent price action, down 3.8% on Wednesday to close at $15.63 after a 1.8% weekly gain, fits the pattern of a stock in a holding pattern between a large short base that has not grown and a catalyst calendar that is now 29 days away.
What to watch: the November 6 earnings print will be the first test of how the market re-prices the regulatory timeline for zipalertinib and whether any update on CLN-978 autoimmune data is enough to shift the short base that has stubbornly sat above 16% of the float for the past several weeks.
See the live data behind this article on ORTEX.
Open CGEM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
